Actelion Protocol AC-055-205: A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients with Pulmonary Hypertension After Left Ventricular Assist Device Implantation Save

Date Added
August 5th, 2016
PRO Number
Pro00053983
Researcher
Patrick Mccann
Keywords
Cardiovascular, Drug Studies, Heart, Pulmonary Arterial Hypertension (PAH), Vascular
Summary

The Actelion SOPRANO study is a prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group Phase II study to evaluate the safety and effect of macitentan on pulmonary vascular resistance in subjects with pulmonary hypertension after left ventricular assist device (LVAD) implantation. Male and female patients 18 years of age or older who have had surgical implantation of LVAD may be eligible to participate in this study.

Study Site:
Palmetto Heart
8 Richland Medical Park
Columbia, SC 29203

Study Site Principal Investigator Contact Information:
Patrick McCann, MD at 803-434-3800

Institution
Palmetto
Recruitment Contact
Patrick McCann
803-434-3800
ClinicalTrialSurvey@PalmettoHealth.org

Change_preferences

-- OR --

Create_login